Resources

Mayo Clinic Store

Websites

Feb. 08, 2017
References
  1. Tefferi A. Diagnostic approach to the patient with polycythemia. http://www.uptodate.com/home. Accessed Nov. 16, 2016.
  2. Polycythemia vera. National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/poly/. Accessed Nov. 16, 2016.
  3. Tefferi A. Prognosis and treatment of polycythemia vera. http://www.uptodate.com/home. Accessed Nov. 16, 2016.
  4. Polycythemia vera facts. Leukemia & Lymphoma Society. https://www.lls.org/llssearch?search-terms=polycythemia+vera&search_language=en. Accessed Nov. 16, 2016.
  5. Mesa RA, et al. Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: A randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology. 2013;31:1285.
  6. Brian JC, et al. Overcoming treatment challenges in myelofibrosis and polycythemia vera: The role of ruxolitinib. Cancer Chemotherapy and Pharmacology. 2016;77:1125.
  7. Geyer H, et al. Symptomatic profiles of patients with polycythemia vera: Implications of inadequately controlled disease. Journal of Clinical Oncology. 2016;34:151.
  8. Polycythemia vera. Merck Manual Professional Version. http://www.merckmanuals.com/professional/hematology-and-oncology/myeloproliferative-disorders/polycythemia-vera. Accessed Nov. 16, 2016.